Christopher Hunley

GSK to launch new development in Hungary

March 16, 2017

GlaxoSmithKline (GSK) is launching a development worth EUR 57 million in its Gödöllõ plant, east of Budapest. Upon completion of the investment, the plant will have expanded activity, producing diphtheria and tetanus vaccine (DT and TT) components for new areas of use.

According to a statement by the Hungarian Investment
Promotion Agency (HIPA), this development project by GSK is a sign of Hungary's
solid reliability as a partner for manufacturing investments with high added
value, which can provide the expertise and scientific background necessary for
innovative manufacturing processes.

2015 figures suggest that
GlaxoSmithKline of Great Britain is the world's eighth largest
research-oriented pharmaceutical and preventive healthcare company. The
products of GSK are available in 150 countries. The company has 89 production
units around the world, with major R&D centers operated in England, the
United States, Belgium and China. The turnover of the company approximated EUR
30 billion in 2015.

The vaccine plant of GSK in
Gödöllõ is one of the world's most modern production units, where the company
has been carrying out production since 2002. The plant plays a key role in the
production of purified diphtheria and tetanus antigens which are used around
the world as a vaccine component. GSK has invested approximately EUR 160
million in the plant during the past 15 years, and currently employs 230 people
at this site.

As a result of the recently
announced investment of EUR 57 million, the Hungarian plant will have expanded
activity, producing diphtheria and tetanus vaccine components for new areas of
use. The plant in Gödöllõ will be the sole internal source of supply of GSK for
producing proteins used as a carrier in the pneumococcus vaccine of GSK, and in
the production of antigens, used for the DTP and polio combination vaccine. As
a result of the investment, the Hungarian plant will more than double its share
of the company's sale of vaccines, tripling its production value, providing
vaccine components that serve to protect billions of infants and small children
around the world.


No comment yet. Be the first!

Leave a Reply

Your email address will not be published. Required fields are marked *

five × 2 =

  • Top 5 Articles

  • Articles by Date

  • Hashtags

  • © Copyright 2020 Duax Kft. –  All rights reserved.